APA (7th ed.) Citation

Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., . . . Loibl, S. (2021). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Annals of oncology, 32(1), . https://doi.org/10.1016/j.annonc.2020.10.471

Chicago Style (17th ed.) Citation

Fasching, Peter Andreas, et al. "Neoadjuvant Paclitaxel/olaparib in Comparison to Paclitaxel/carboplatinum in Patients with HER2-negative Breast Cancer and Homologous Recombination Deficiency (GeparOLA Study)." Annals of Oncology 32, no. 1 (2021). https://doi.org/10.1016/j.annonc.2020.10.471.

MLA (9th ed.) Citation

Fasching, Peter Andreas, et al. "Neoadjuvant Paclitaxel/olaparib in Comparison to Paclitaxel/carboplatinum in Patients with HER2-negative Breast Cancer and Homologous Recombination Deficiency (GeparOLA Study)." Annals of Oncology, vol. 32, no. 1, 2021, https://doi.org/10.1016/j.annonc.2020.10.471.